Calidi Biotherapeutics, Inc. Common Stock CLDI 深 沪
等待开盘 09-02 09:30:00 美东时间
1.65
-0.060
-3.51%
华盛通- 最 高1.74
- 今 开1.71
- 成交量 31.31万股
- 最 低 1.59
- 昨 收 1.71
- 总市值 474.66万
- 52周最高 46.68
- 市盈率 静 --
- 换手率 10.89%
- 52周最低 1.54
- 委 比 -80.18%
- 总股本 287.67万
- 历史最高 2886.00
- 量 比 0.53
- 振 幅 8.77%
- 历史最低 1.59
- 每 手 1
- 风险率 6.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Calidi Biotherapeutics Updates Presentation Disclosure
Calidi Biotherapeutics ( ($CLDI) ) just unveiled an update. On August 29, 2025,...
08-30 05:51
Calidi Biotherapeutics Completes $6.9M Public Offering
An announcement from Calidi Biotherapeutics ( ($CLDI) ) is now available. On Au...
08-23 05:47
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
Calidi Biotherapeutics priced a $6 million underwritten public offering, including 1,472,764 common stock units at $2.00 each and 1,528,000 pre-funded warrant units at $1.999 each. The Series I warrants have an exercise price of $2.00 and a five-year term. Ladenburg Thalmann is the sole book-running manager, with Laidlaw as a co-manager. Calidi granted underwriters a 45-day option to purchase up to an additional 450,000 shares or warrants. The of...
08-20 13:15
Calidi files to sell 1.2M common stock units
Calidi Biotherapics (NYSE:CLDI) filed to sell 1.2M common stock units. Filing More on Calidi Biotherapeutics Seeking Alpha’s Quant Rating on Calidi Biotherapeutics Historical earnings data for Calidi ...
08-16 05:30
Calidi Biotherapeutics Announces Executive Departure Agreement
Calidi Biotherapeutics ( ($CLDI) ) has issued an update. Calidi Biotherapeutics...
08-15 05:51
Calidi Biotherapeutics GAAP EPS of -$1.99
Calidi Biotherapeutics press release (NYSE:CLDI): Q2 GAAP EPS of -$1.99. The company had approximately $5.3 million in cash and $0.1 million in restricted cash as of June 30, 2025, compared to $9.6 mi...
08-11 18:22
Calidi Biotherapeutics Q2 EPS $(1.99) Misses $(0.11) Estimate
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate of $(0.11) by 1709.09 percent. This is a 88.12 percent increase over losses of $(16.75) per
08-09 04:16
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics reported Q2 2025 results, highlighting key advancements including preclinical data for CLD-401 at ASCO, FDA Fast Track Designation for CLD-201 for soft tissue sarcoma, and $4.6 million raised through a warrant offering. The company also detailed financials showing a net loss of $5.7 million and reduced cash reserves. Calidi remains focused on advancing its RedTail platform for targeted therapies in oncology.
08-08 20:15
Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split
An announcement from Calidi Biotherapeutics ( ($CLDI) ) is now available. Calid...
08-08 05:44
Calidi Biotherapeutics shares are trading higher after the company announced it has received FDA Fast Track Designation for CLD-201.
Calidi Biotherapeutics shares are trading higher after the company announced it...
07-29 20:07
